<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuznar, Wayne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">O'Dell, James R.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Experts Debate Triple Therapy versus Biologics as Treatment for RA</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-01-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-11</style></pages><abstract><style  face="normal" font="default" size="100%">Whether a biologic response modifier or triple disease-modifying antirheumatic drug (DMARD) therapy should be the mainstay of treatment for patients with rheumatoid arthritis (RA) is a subject for debate. This article compares triple conventional DMARD therapy versus biologic agents for the treatment of RA.</style></abstract><number><style face="normal" font="default" size="100%">18</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>